Biobanking Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

The Global Biobanking Market was valued at USD 76.2 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 164.5 billion by 2034.

The growing focus on personalized medicine, together with rising investments in genomics and molecular biology research, is strongly propelling market expansion. Biobanks play an essential role in biomedical innovation, enabling the systematic collection, preservation, and analysis of biological specimens such as blood, tissues, and DNA for clinical and therapeutic purposes. Increasing participation in national biobank programs and heightened public awareness of genomic data utilization are reinforcing the industry’s importance in modern healthcare. The growing integration of digital platforms and data-sharing technologies is also enhancing global collaboration among research institutes, pharmaceutical companies, and healthcare providers. As the healthcare industry shifts toward data-driven and precision-based medical approaches, biobanking is emerging as a critical infrastructure that supports large-scale population studies, precision diagnostics, and drug discovery. The ongoing development of standardized biobanking protocols, along with automation in storage and sample management, continues to strengthen operational efficiency and improve the accessibility of biological materials for scientific and clinical use.

In 2024, the equipment segment held a 42.5% share, supported by the growing adoption of advanced cryogenic freezers, ultra-low temperature storage units, and automated handling systems. This segment is further divided into sample storage, transport, processing, and analytical equipment. Increasing demand for high-capacity and reliable storage solutions is driven by large-scale genomic research and biopharmaceutical initiatives. Advanced equipment helps maintain biospecimen integrity while reducing manual handling errors, ensuring that samples remain viable for long-term use in both clinical and research environments.

The blood products segment held a 30.3% share in 2024, owing to the extensive use of blood samples in biomarker identification, genetic testing, and clinical diagnostics. The segment benefits from the standardized procedures for collection and preservation that make blood one of the most versatile biospecimens available. Blood samples are widely utilized in a range of studies, including immunology, epidemiology, and metabolic research, which further strengthens their contribution to biobanking. Their importance in disease surveillance, clinical testing, and public health research continues to reinforce this segment’s leading position.

North America Biobanking Market held 45.7% share in 2024, supported by a strong presence of established healthcare infrastructure and advanced genomic research initiatives. The U.S. and Canada lead the region’s growth, driven by increased focus on precision medicine, cancer research, and advanced biospecimen management practices. Government initiatives and academic collaborations are promoting the expansion of national biobanks, enabling efficient collection and utilization of biological samples for clinical and pharmaceutical research. The high adoption of digital biobanking systems and automation technologies is further enhancing data accessibility and quality, promoting faster progress in personalized therapy development.

Key companies operating in the Global Biobanking Market include Thermo Fisher Scientific, Avantor, Becton, Dickinson and Company, Azenta, Cryoport, BioIVT, Merck & Co., Pfizer, Charles River Laboratories, STEMCELL Technologies, Qiagen, Labcorp, Tecan Trading, PHC Holdings, Eurofins Scientific, Hamilton Company, BioStorage Technologies, Brooks Life Sciences, and Novartis. Leading players in the biobanking market are employing multiple strategies to strengthen their market presence and competitive position. Many are expanding their global biobank networks and investing in automation to streamline sample handling and improve scalability. Strategic mergers, acquisitions, and collaborations are pursued to enhance data integration, sample diversity, and operational efficiency. Companies are also focusing on developing cloud-based biobank management platforms and advanced cryogenic storage solutions to ensure high-quality sample preservation.

Comprehensive Market Analysis and Forecast

• Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
• Competitive landscape with Porter’s Five Forces and PESTEL analysis
• Market size, segmentation, and regional forecasts
• In-depth company profiles, business strategies, financial insights, and SWOT analysis

This product will be delivered within 2-4 business days.